-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

-Live Mint I&B minister raises prospect of independent broadcasting authority, says govt may be forced to set up ratings system Information and broadcasting (I&B) minister Manish Tewari on Friday raised the prospect of an independent broadcasting authority and said the government may be forced to set up a ratings system unless the industry took steps to put in place a credible method of ranking television programmes, in a series of statements that...

-The Indian Express India is no insecure dictatorship junking international obligations for cheap populism. The highest court of the world's largest democracy has made a nuanced distinction between real Innovation and marketing gimmickry. Yet, the Swiss pharmaceutical giant Novartis's response to the recent Supreme Court verdict in Novartis vs Union of India has been imperial in tone. The judgment "discourages innovative drug discovery", it claimed. It accused Indian law of lagging...

-The Economic Times MUMBAI: India's strong stance on minor drug Innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental Innovations should be checked and that...

-The Guardian Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor   The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms. A decade or so ago, it was mostly about access to Aids drugs. Firms...